Refractory Epilepsy in a Toddler With PPP2R1A Gene Mutation and Congenital Hydrocephalus

Review began 10/20/2021
Review ended 11/22/2021
Published 11/29/2021

© Copyright 2021

Ruxmohan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Samir Ruxmohan¹, Jonathan Quinonez², Randhir S. Yadav³, Shumneva Shrestha⁴, Sujan Poudel^{5,6}, Joel D. Stein^{7,8}

1. Neurology, Larkin Community Hospital, Miami, USA 2. Neurology/Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, USA 3. Department of Internal Medicine, Institute of Medicine, Tribhuvan University, Kathmandu, NPL 4. Department of Pediatrics, Tribhuvan University Institute of Medicine, Kathmandu, NPL 5. Psychiatry and Behavioral Sciences, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 6. Division of Research & Academic Affairs, Larkin Community Hospital, South Miami, USA 7. Osteopathic Neuromuscular Medicine, Family Medicine, Sports Medicine, Pain Medicine, Lake Erie College of Osteopathic Medicine (LECOM) Bradenton, Bradenton, FL, USA 8. Pain Management, Osteopathic Neuromuscular Medicine, Sports Medicine, Larkin Community Hospital, South Miami, FL, USA

Corresponding author: Jonathan Quinonez, jquinonez@larkinhospital.com

Abstract

Protein phosphatase 2A (PP2A) is a serine-threonine phosphatase that controls a variety of cellular functions. The *PPP2R1A* gene is present on chromosome 19 (19q13.41). Its mutation can interrupt B56δ-dependent dephosphorylation where B56δ is greatly expressed in the neural tissues. We present a case of a 14-month-old boy with infantile spasms, developmental delay, obstructive sleep apnea, *PPP2R1A* gene mutation, congenital hydrocephalus, hypoplastic/absent corpus callosum, pontocerebellar hypoplasia, and medically refractory seizures. He underwent multiple surgical procedures that include endoscopic third ventriculostomy with choroid plexus cauterization, ventriculoperitoneal shunting, and external ventricular drain for progressive hydrocephalus with multiple antiepileptic regimes for refractory epilepsy with variable response.

Categories: Neurology, Neurosurgery, Osteopathic Medicine

Keywords: refractory epilepsy, external ventricular drain, all neurology, developmental delay, *ppp2r1a*

Introduction

Epilepsy is a common neurological disorder of major health concern. Globally, 1% of the population has active epilepsy [1]. A population-based study estimated 10% of the population will have at least one episode of seizure during their lifetime [2]. Even in countries with adequate facilities to diagnose and treat, 30-40% of people with epilepsy are noted to have uncontrolled seizures [1].

Case Presentation

We present a case of a 14-month-old male with a past medical history of congenital hydrocephalus, infantile spasms, developmental delay, *PPP2R1A* gene mutation, obstructive sleep apnea, and medically refractory seizures who presented to a local hospital for evaluation of an increased seizure frequency, fever, and non-bilious/non-bloody emesis of four days duration. His past surgical history consisted of prior interventions that included a choroid plexus cauterization and a ventriculoperitoneal placement. On physical examination, he had macrocephaly with frontal bossing. He was awake with eyes open with upward gaze preference. There were intermittent non-purposeful movements of all extremities, decreased muscle bulk, axial hypotonia with distal extremity hypertonia, arching with slight opisthonic posturing and reflexes were 3+ bilaterally. An MRI of his brain without contrast showed hypoplastic/absent corpus callosum, pontocerebellar hypoplasia. A video electroencephalogram (vEEG) demonstrated showed epileptiform discharges from the left central region and recording consistent with epileptiform encephalopathy. In addition, a videofluoroscopic swallow study (VFSS) done showed functional airway protection with thin liquids. He was placed on levetiracetam and phenobarbital and admitted for further management.

After admission, given the past few days of increased seizure frequency, a prolonged seizure on admission, lacosamide was loaded and continued on maintenance dose with no recurrent seizure. He tolerated the new anti-epileptic regimen. With a concern for ongoing breakthrough seizures, he was placed back on vEEG for further characterization. Compared to the last one done about four months back, the vEEG showed worsening of epileptiform discharges; a bilateral independent region with severe epileptic encephalopathy. Consequently, a medication adjustment with clobazam was made. His parents requested to wean off levetiracetam as they didn't believe it has helped, so clobazam was further optimized and levetiracetam was weaned off. He was also prescribed with rescue medicine diazepam per rectal and clonazepam as needed on sick days. He was also kept on cannabidiol and a ketogenic diet.

He was later taken to the operating room for removal of right strata ventroperitoneal shunt (VPS) due to

How to cite this article

Ruxmohan S, Quinonez J, Yadav R S, et al. (November 29, 2021) Refractory Epilepsy in a Toddler With *PPP2R1A* Gene Mutation and Congenital Hydrocephalus. *Cureus* 13(11): e19988. DOI 10.7759/cureus.19988

meningitis/encephalitis [cerebrospinal fluid (CSF) culture showed methicillin-susceptible *Staphylococcus aureus*) and insertion of a tunneled external ventricular drain (EVD); however, an MRI of his brain without contrast gave concern for EVD dislodgement. He underwent another exploratory surgery to ensure that his EVD was in place and had a repeat MRI one week later which demonstrated an intact EVD.

As this patient already was diagnosed with a PPP2R1A gene mutation prior to presentation, management during her hospital course focused solely on seizure prevention and EVD dislodgement. No genetic analysis was indicated for further evaluation of the patient's increased seizure frequency.

Discussion

PPP2R1A is a serine-threonine phosphatase that regulates a variety of cellular functions. It is a heterotrimeric protein composed of (A) a scaffolding subunit, (B) variable regulatory subunits, and (C) a catalytic subunit [3]. The PPP2R1A gene is present on chromosome 19 (19q13.41) which encodes isoform α of the scaffolding subunit (A α). The A α scaffolding subunit functions to link the catalytic and regulatory subunits including B56 δ [4]. Moreover, mutations in the PPP2R1A gene can interrupt B56 δ -dependent dephosphorylation [4] where B56 δ is greatly expressed in the neural tissues [4,5]. Seven cases of de novo mutations in the PPP2R1A gene have been described in the literature with predominant features of agenesis or hypoplasia of corpus callosum, hypotonia, developmental delay, severe intellectual disability, ventriculomegaly, and dysmorphic features [4-7]. These features were consistent with findings in our patient. Most recently, a broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorder in 30 individuals found language delay, hypotonia, and hypermobile joints along developmental delay ranging from mild learning to severe intellectual disabilities (ID) with or without epilepsy. Individuals without B55 α subunit-binding deficit had macrocephaly, less severe ID, and no seizures while impaired B55 α but increased striatin binding were found biochemically more disruptive variants with associated profound ID, epilepsy, hypoplasia of corpus callosum, and occasionally microcephaly [8].

Hydrocephalus is a condition of increased intraventricular pressure and pathological dilatation of ventricles which has significantly caused morbidity and mortality in children [9]. Among the myriad of clinical features, Cushing's triad (hypertension, bradycardia, and irregular respiration) is the most common presentation but may vary according to the age of presentation [10]. These were consistent in our patient. Besides, some late manifestations like Parinaud syndrome (dorsal midbrain syndrome) and new-onset seizures necessitate urgent intervention [10]. A seizure should be considered a sign of an advanced form of hydrocephalus if there is no other explainable cause [10]. Thus, intervention for advanced stage hydrocephalus is required [10]. Imaging studies are useful in diagnosing hydrocephalus while serial head circumference measurement can help monitor the progress [10]. In children showing progressive features of hydrocephalus, CSF diversion procedures remain the standard of care where the ventricular shunt is the most common one [10]. Alternately, newer endoscopic minimally invasive procedures can also be used [10]. The five-year outcome in International Infant Hydrocephalus Study (IIHS) showed a better overall health status and quality of life in the endoscopic third ventriculostomy (ETV) cohort but no significant difference between those treated initially with ETV or shunt [11-14]. The immediate risks of surgical procedures for hydrocephalus include strokes, intraparenchymal or subdural hemorrhage, catheter misplacement causing nonfunctional shunt, or urgent reoperation [10,15-19]. In our patient, hydrocephalus was confirmed on MRI. Further, surgical procedure ETV/choroid plexus catheterization (CPC) was done to drain the CSF. He developed meningitis/encephalitis so EVD was placed later. But it also got dislodged which was repositioned.

Conclusions

Managing seizures can be a great challenge in a child with PPP2R1A gene mutation and congenital hydrocephalus. Different standard medical and surgical treatments may show variable effects on symptom control and disease progression.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Kobau R, Zahran H, Thurman DJ, et al.: Epilepsy surveillance among adults--19 States, Behavioral Risk Factor Surveillance System, 2005. *System.* 2005, 2008:1-20.
2. Hesdorffer DC, Logrosino G, Benn EK, Katri N, Cascino G, Hauser WA: Estimating risk for developing

- epilepsy: a population-based study in Rochester, Minnesota. *Neurology*. 2011, 76:23-7. [10.1212/WNL.0b013e318204a36a](https://doi.org/10.1212/WNL.0b013e318204a36a)
3. Seshacharyulu P, Pandey P, Datta K, Batra SK: Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. *Cancer Lett*. 2013, 335:9-18. [10.1016/j.canlet.2013.02.036](https://doi.org/10.1016/j.canlet.2013.02.036)
4. Houge G, Haesen D, Vissers LE, et al.: B56b-related protein phosphatase 2A dysfunction identified in patients with intellectual disability. *J Clin Invest*. 2015, 125:3051-62. [10.1172/JCI79860](https://doi.org/10.1172/JCI79860)
5. Louis JV, Martens E, Borghgraef P, et al.: Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. *Proc Natl Acad Sci U S A*. 2011, 108:6957-62. [10.1073/pnas.1018777108](https://doi.org/10.1073/pnas.1018777108)
6. Wallace A, Caruso P, Karaa A: A newborn with severe ventriculomegaly: expanding the PPP2R1A gene mutation phenotype. *J Pediatr Genet*. 2019, 8:240-3. [10.1055/s-0039-1692414](https://doi.org/10.1055/s-0039-1692414)
7. Zhang Y, Li H, Wang H, Jia Z, Xi H, Mao X: A de novo variant identified in the PPP2R1A gene in an infant induces neurodevelopmental abnormalities. *Neurosci Bull*. 2020, 36:179-82. [10.1007/s12264-019-00430-4](https://doi.org/10.1007/s12264-019-00430-4)
8. Lenaerts L, Reynhout S, Verbinnen I, et al.: The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction. *Genet Med*. 2021, 23:352-62. [10.1038/s41436-020-00981-2](https://doi.org/10.1038/s41436-020-00981-2)
9. Jeng S, Gupta N, Wrensch M, Zhao S, Wu YW: Prevalence of congenital hydrocephalus in California, 1991-2000. *Pediatr Neurol*. 2011, 45:67-71. [10.1016/j.pediatrneurol.2011.03.009](https://doi.org/10.1016/j.pediatrneurol.2011.03.009)
10. Wright Z, Larrew TW, Eskandari R: Pediatric hydrocephalus: current state of diagnosis and treatment. *Pediatr Rev*. 2016, 37:478-90. [10.1542/pir.2015-0134](https://doi.org/10.1542/pir.2015-0134)
11. Kulkarni AV, Sgouros S, Leitner Y, Constantini S: International Infant Hydrocephalus Study (IIHS): 5-year health outcome results of a prospective, multicenter comparison of endoscopic third ventriculostomy (ETV) and shunt for infant hydrocephalus. *Childs Nerv Syst*. 2018, 34:2391-7. [10.1007/s00381-018-3896-5](https://doi.org/10.1007/s00381-018-3896-5)
12. Falco-Walter JJ, Bleck T: Treatment of established status epilepticus. *J Clin Med*. 2016, 5:10.3390/jcm5050049
13. Trinka E, Cock H, Hesdorffer D, et al.: A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. *Epilepsia*. 2015, 56:1515-23. [10.1111/epi.13121](https://doi.org/10.1111/epi.13121)
14. Löscher W: Molecular mechanisms of drug resistance in status epilepticus. *Epilepsia*. 2009, 50 Suppl 12:19-21. [10.1111/j.1528-1167.2009.02367.x](https://doi.org/10.1111/j.1528-1167.2009.02367.x)
15. Riviello JJ Jr, Ashwal S, Hirtz D, et al.: Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. 2006, 67:1542-50. [10.1212/01.wnl.0000243197.05519.3d](https://doi.org/10.1212/01.wnl.0000243197.05519.3d)
16. Chamberlain JM, Kapur J, Shinnar S, et al.: Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. *Lancet*. 2020, 395:1217-24. [10.1016/S0140-6736\(20\)30611-5](https://doi.org/10.1016/S0140-6736(20)30611-5)
17. Appleton RE, Rainford NE, Gamble C, et al.: Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT. *Health Technol Assess*. 2020, 24:1-96. [10.3310/hta24580](https://doi.org/10.3310/hta24580)
18. Jayalakshmi S, Panigrahi M, Nanda SK, Vadapalli R: Surgery for childhood epilepsy. *Ann Indian Acad Neurol*. 2014, 17:S69-79. [10.4103/0972-2327.128665](https://doi.org/10.4103/0972-2327.128665)
19. Dagar A, Chandra PS, Chaudhary K, et al.: Epilepsy surgery in a pediatric population: a retrospective study of 129 children from a tertiary care hospital in a developing country along with assessment of quality of life. *Pediatr Neurosurg*. 2011, 47:186-93. [10.1159/000334257](https://doi.org/10.1159/000334257)